SG11201606316XA - Methods of treating alzheimer's disease - Google Patents

Methods of treating alzheimer's disease

Info

Publication number: SG11201606316XA
Authority: SG; Singapore
Prior art keywords: disease; methods; treating alzheimer; alzheimer; treating
Prior art date: 2014-02-08

Application number

SG11201606316XA

Inventor

William Cho

Michel Friesenhahn

Robert Paul

Michael Ward

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-02-08

Filing date

2015-02-06

Publication date

2016-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52684643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201606316X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-02-06 Application filed by Genentech Inc filed Critical Genentech Inc

2016-08-30 Publication of SG11201606316XA publication Critical patent/SG11201606316XA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG11201606316XA 2014-02-08 2015-02-06 Methods of treating alzheimer's disease SG11201606316XA (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201461937472P	2014-02-08	2014-02-08
US201461971479P	2014-03-27	2014-03-27
US201462010259P	2014-06-10	2014-06-10
US201462081992P	2014-11-19	2014-11-19
PCT/US2015/014758 WO2015120233A1 (en)	2014-02-08	2015-02-06	Methods of treating alzheimer's disease

Publications (1)

Publication Number	Publication Date
SG11201606316XA true SG11201606316XA (en)	2016-08-30

Family

ID=52684643

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201606316XA SG11201606316XA (en)	2014-02-08	2015-02-06	Methods of treating alzheimer's disease
SG10201913637RA SG10201913637RA (en)	2014-02-08	2015-02-06	Methods of treating alzheimer's disease

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201913637RA SG10201913637RA (en)	2014-02-08	2015-02-06	Methods of treating alzheimer's disease

Country Status (19)

Country	Link
US (3)	US20150246963A1 (en)
EP (2)	EP3102231B1 (en)
JP (4)	JP6685912B2 (en)
KR (4)	KR20240094017A (en)
CN (1)	CN106163548A (en)
AU (1)	AU2015214058B2 (en)
BR (1)	BR112016018170A2 (en)
CA (1)	CA2938466C (en)
CL (2)	CL2016001979A1 (en)
HK (1)	HK1231401A1 (en)
IL (1)	IL246999B (en)
MX (1)	MX380252B (en)
MY (1)	MY179105A (en)
NZ (1)	NZ723884A (en)
RU (1)	RU2724190C2 (en)
SG (2)	SG11201606316XA (en)
TW (1)	TWI705824B (en)
WO (1)	WO2015120233A1 (en)
ZA (1)	ZA201605341B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT3119911T (en) *	2014-03-21	2023-11-03	Alzheon Inc	Methods for treating neurological disorders
MA41115A (en)	2014-12-02	2017-10-10	Biogen Int Neuroscience Gmbh	ALZHEIMER'S DISEASE TREATMENT PROCESS
GB2541003A (en) *	2015-08-05	2017-02-08	Kran Life Sciences Llp	Neurodegenerative disorders
HRP20230809T1 (en) *	2015-09-10	2023-10-27	Alzheon, Inc.	Treatment of alzheimer's disease in a particular patient population
EP3368563A1 (en) *	2015-10-28	2018-09-05	The Trustees Of The University Of Pennsylvania	Intrathecal administration of adeno-associated-viral vectors for gene therapy
CN114019170A (en) *	2016-01-20	2022-02-08	基因泰克公司	High dose treatment for alzheimer's disease
MA45149A (en) *	2016-06-07	2019-04-10	Biogen Int Neuroscience Gmbh	METHODS OF TREATMENT OF ALZHEIMER'S DISEASE
US20190167611A1 (en) *	2016-07-29	2019-06-06	Biogen Chesapeake Llc	Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment
IT201600118499A1 (en) *	2016-11-25	2018-05-25	Giacomo Koch	Use of dopaminergic agonists for the prevention of early stage Alzheimer's disease progression.
WO2018207154A1 (en) *	2017-05-12	2018-11-15	The Hong Kong University Of Science And Technology	Heterocyclic compounds as epha4 inhibitors
KR20250053967A (en)	2017-08-22	2025-04-22	바이오젠 엠에이 인코포레이티드	Pharmaceutical compositions containing anti-beta amyloid antibodies
WO2019182319A1 (en) *	2018-03-20	2019-09-26	(주)인벤티지랩	Method for preparing pharmaceutical composition for preventing or treating cognitive disorder-associated diseases, and pharmaceutical composition for preventing or treating cognitive disorder-associated diseases, prepared by preparation method
KR102224918B1 (en)	2018-03-20	2021-03-09	(주)인벤티지랩	Pharmaceutiical composition comprising memantine and donepezil for preventing or treating cognitive impairment-related disease and preparation method thereof
JP7532259B2 (en) *	2018-04-05	2024-08-13	プレックスファーマスーティカルズ，インク	Eye disease treatment drugs
JP2024526880A (en)	2021-07-22	2024-07-19	ジェネンテック，インコーポレイテッド	Brain targeting compositions and methods of use thereof
WO2025245381A1 (en)	2024-05-23	2025-11-27	The Trustrees Of Dartmouth College	Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (en)	1987-03-18	1999-04-22	Sb2, Inc., Danville, Calif.	CHANGED ANTIBODIES.
ATE102631T1 (en)	1988-11-11	1994-03-15	Medical Res Council	CLONING OF IMMUNOGLOBULIN SEQUENCES FROM THE VARIABLE DOMAINS.
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en)	1990-12-03	2003-02-04	Lisa J. Garrard	Enrichment method for variant proteins with altered binding properties
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en)	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
EP0604580A1 (en)	1991-09-19	1994-07-06	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572A7 (en)	1991-10-07	1994-05-27	Oncologix Inc	Combination and method of use of anti-erbB-2 monoclonal antibodies
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
DE69334255D1 (en)	1992-02-06	2009-02-12	Novartis Vaccines & Diagnostic	Marker for cancer and biosynthetic binding protein for it
WO1994029351A2 (en)	1993-06-16	1994-12-22	Celltech Limited	Antibodies
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
JP2002506353A (en)	1997-06-24	2002-02-26	ジェネンテック・インコーポレーテッド	Methods and compositions for galactosylated glycoproteins
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
WO1999022764A1 (en)	1997-10-31	1999-05-14	Genentech, Inc.	Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
BR9813365A (en)	1997-12-05	2004-06-15	Scripps Research Inst	Method for Production and Humanization of a Mouse Monoclonal Antibody
PT1068241E (en)	1998-04-02	2007-11-19	Genentech Inc	Antibody variants and fragments thereof
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
DK1071700T3 (en)	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity
US20030175884A1 (en)	2001-08-03	2003-09-18	Pablo Umana	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR101077001B1 (en)	1999-01-15	2011-10-26	제넨테크, 인크.	Polypeptide Variants with Altered Effector Function
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
AU3672800A (en)	1999-04-09	2000-11-14	Kyowa Hakko Kogyo Co. Ltd.	Method for controlling the activity of immunologically functional molecule
DE60022369T2 (en)	1999-10-04	2006-05-18	Medicago Inc., Sainte Foy	PROCESS FOR REGULATING THE TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NITROGEN
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
EP1229125A4 (en)	1999-10-19	2005-06-01	Kyowa Hakko Kogyo Kk	PROCESS FOR PRODUCING A POLYPEPTIDE
CA2393869A1 (en)	1999-12-15	2001-06-21	Genetech,Inc.	Shotgun scanning, a combinatorial method for mapping functional protein epitopes
MXPA02010011A (en)	2000-04-11	2003-04-25	Genentech Inc	Multivalent antibodies and uses therefor.
HU231090B1 (en)	2000-10-06	2020-07-28	Kyowa Kirin Co., Ltd.	Cells producing antibody compositions
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
ES2405944T3 (en)	2000-11-30	2013-06-04	Medarex, Inc.	Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal mice zadas
ATE430580T1 (en)	2001-10-25	2009-05-15	Genentech Inc	GLYCOPROTEIN COMPOSITIONS
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
CA2481837A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Production process for antibody composition
WO2003085102A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1498485A4 (en)	2002-04-09	2006-09-06	Kyowa Hakko Kogyo Kk	CELLS WITH MODIFIED GENOM
EP1498491A4 (en)	2002-04-09	2006-12-13	Kyowa Hakko Kogyo Kk	METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
JP4832719B2 (en)	2002-04-09	2011-12-07	協和発酵キリン株式会社	Medicine containing antibody composition for FcγRIIIa polymorphism patients
WO2003084569A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Drug containing antibody composition
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CN103833854B (en)	2002-12-16	2017-12-12	健泰科生物技术公司	Immunoglobulin variants and application thereof
US20050079574A1 (en)	2003-01-16	2005-04-14	Genentech, Inc.	Synthetic antibody phage libraries
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2542046A1 (en)	2003-10-08	2005-04-21	Kyowa Hakko Kogyo Co., Ltd.	Fused protein composition
EP1705251A4 (en)	2003-10-09	2009-10-28	Kyowa Hakko Kirin Co Ltd	PROCESS FOR PREPARING ANTIBODY COMPOSITION USING THE FUNCTION OF A1,6-FUCOSYLTRANSFERASE HEMOMING RNA
BRPI0416262B1 (en)	2003-11-05	2022-04-12	Roche Glycart Ag	Humanized type II anti-human cd20 antibody, its production method, its uses, as well as isolated polynucleotide, expression vector and pharmaceutical composition
JPWO2005053742A1 (en)	2003-12-04	2007-06-28	協和醗酵工業株式会社	Medicament containing antibody composition
MXPA06011199A (en)	2004-03-31	2007-04-16	Genentech Inc	Humanized anti-tgf-beta antibodies.
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
WO2005100402A1 (en)	2004-04-13	2005-10-27	F.Hoffmann-La Roche Ag	Anti-p-selectin antibodies
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
CN101065151B (en)	2004-09-23	2014-12-10	健泰科生物技术公司	Cysteine engineered antibodies and conjugates
JO3000B1 (en)	2004-10-20	2016-09-05	Genentech Inc	Antibody Formulations.
TW200636066A (en) *	2004-12-15	2006-10-16	Elan Pharm Inc	Humanized antibodies that recognize beta amyloid peptide
WO2007056441A2 (en)	2005-11-07	2007-05-18	Genentech, Inc.	Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
CN101506236B (en) *	2005-11-30	2012-12-12	雅培制药有限公司	Monoclonal antibody against amyloid beta protein and use thereof
WO2007064919A2 (en)	2005-12-02	2007-06-07	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
RU2551782C2 (en) *	2005-12-12	2015-05-27	Ац Иммуне Са	Anti-amyloid beta (a beta) 1-42 monoclonal antibodies possessing therapeutic properties
AR060871A1 (en)	2006-05-09	2008-07-16	Genentech Inc	UNION OF POLYPEPTIDES WITH OPTIMIZED SUPERCONTIGES
TWI551607B (en) *	2006-07-14	2016-10-01	Ａｃ免疫公司	Humanized antibody
US10118970B2 (en)	2006-08-30	2018-11-06	Genentech, Inc.	Multispecific antibodies
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (en)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	Liquid crystal display panel driving device and driving method thereof
JO3076B1 (en) *	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	Immunotherapy regimes dependent on apoe status
ES2563027T3 (en)	2008-01-07	2016-03-10	Amgen Inc.	Method for manufacturing antibody Fc heterodimer molecules using electrostatic conduction effects
EA201291040A1 (en) *	2010-04-13	2013-04-30	Бакстер Интернэшнл Инк.	USE OF THE VELOCITY INCREASE DURING THE TREATMENT OF ALCEHEMER'S Disease By Intravenous Immunoglobulin
CN103179981B (en) *	2010-07-30	2017-02-08	Ac免疫有限公司	Safe and functional humanized antibodies
JP2014001232A (en) *	2013-09-02	2014-01-09	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic disease

2015
- 2015-02-06 KR KR1020247018360A patent/KR20240094017A/en not_active Withdrawn
- 2015-02-06 TW TW104104180A patent/TWI705824B/en active
- 2015-02-06 HK HK17105176.6A patent/HK1231401A1/en unknown
- 2015-02-06 EP EP15710295.5A patent/EP3102231B1/en active Active
- 2015-02-06 CN CN201580017492.8A patent/CN106163548A/en active Pending
- 2015-02-06 SG SG11201606316XA patent/SG11201606316XA/en unknown
- 2015-02-06 MX MX2016010173A patent/MX380252B/en unknown
- 2015-02-06 KR KR1020167024829A patent/KR20160111039A/en not_active Ceased
- 2015-02-06 MY MYPI2016702789A patent/MY179105A/en unknown
- 2015-02-06 AU AU2015214058A patent/AU2015214058B2/en active Active
- 2015-02-06 SG SG10201913637RA patent/SG10201913637RA/en unknown
- 2015-02-06 KR KR1020237013210A patent/KR20230056800A/en not_active Ceased
- 2015-02-06 JP JP2016550529A patent/JP6685912B2/en active Active
- 2015-02-06 EP EP19188687.8A patent/EP3718563A1/en not_active Withdrawn
- 2015-02-06 WO PCT/US2015/014758 patent/WO2015120233A1/en not_active Ceased
- 2015-02-06 RU RU2016136081A patent/RU2724190C2/en active
- 2015-02-06 KR KR1020217030556A patent/KR20210121288A/en not_active Ceased
- 2015-02-06 US US14/616,261 patent/US20150246963A1/en not_active Abandoned
- 2015-02-06 BR BR112016018170-0A patent/BR112016018170A2/en not_active Application Discontinuation
- 2015-02-06 NZ NZ723884A patent/NZ723884A/en unknown
- 2015-02-06 CA CA2938466A patent/CA2938466C/en active Active
2016
- 2016-07-28 IL IL246999A patent/IL246999B/en active IP Right Grant
- 2016-08-02 ZA ZA2016/05341A patent/ZA201605341B/en unknown
- 2016-08-05 CL CL2016001979A patent/CL2016001979A1/en unknown
2017
- 2017-11-03 CL CL2017002781A patent/CL2017002781A1/en unknown
2019
- 2019-12-20 JP JP2019230200A patent/JP2020073507A/en active Pending
2020
- 2020-02-05 US US16/782,654 patent/US20200399352A1/en not_active Abandoned
2021
- 2021-08-04 US US17/394,053 patent/US20220195020A1/en not_active Abandoned
- 2021-12-17 JP JP2021204857A patent/JP2022058369A/en not_active Withdrawn
2023
- 2023-12-14 JP JP2023210860A patent/JP2024037893A/en active Pending

Also Published As

Publication number	Publication date
US20150246963A1 (en)	2015-09-03
TWI705824B (en)	2020-10-01
JP6685912B2 (en)	2020-04-22
TW201613636A (en)	2016-04-16
IL246999B (en)	2020-09-30
JP2017511793A (en)	2017-04-27
KR20240094017A (en)	2024-06-24
MX380252B (en)	2025-03-12
JP2020073507A (en)	2020-05-14
JP2024037893A (en)	2024-03-19
MY179105A (en)	2020-10-28
CA2938466C (en)	2021-11-02
HK1231401A1 (en)	2017-12-22
EP3718563A1 (en)	2020-10-07
CN106163548A (en)	2016-11-23
KR20210121288A (en)	2021-10-07
RU2016136081A (en)	2018-03-13
CA2938466A1 (en)	2015-08-13
AU2015214058A1 (en)	2016-08-11
CL2016001979A1 (en)	2017-02-10
JP2022058369A (en)	2022-04-12
MX2016010173A (en)	2016-10-13
NZ723884A (en)	2023-02-24
US20200399352A1 (en)	2020-12-24
EP3102231B1 (en)	2019-09-11
RU2016136081A3 (en)	2018-09-28
ZA201605341B (en)	2021-01-27
KR20230056800A (en)	2023-04-27
AU2015214058B2 (en)	2020-07-09
RU2724190C2 (en)	2020-06-23
BR112016018170A2 (en)	2018-02-20
US20220195020A1 (en)	2022-06-23
WO2015120233A1 (en)	2015-08-13
KR20160111039A (en)	2016-09-23
SG10201913637RA (en)	2020-03-30
EP3102231A1 (en)	2016-12-14
IL246999A0 (en)	2016-09-29
CL2017002781A1 (en)	2018-04-13

Publication	Publication Date	Title
IL285722A (en)	2021-09-30	Methods for treating alzheimer's disease
IL283561B (en)	2022-01-01	Methods for treating ocular diseases
IL247085A0 (en)	2016-09-29	Methods of treating alzheimer's disease
ZA201605341B (en)	2021-01-27	Methods of treating alzheimer's disease
IL276315A (en)	2020-09-30	Donepezil compositions and method of treating alzheimer's disease
SG11201701723XA (en)	2017-04-27	Methods of treating liver disease
IL253244A0 (en)	2017-08-31	Methods of treating retinal diseases
GB201701673D0 (en)	2017-03-15	Methods of well treatment
SG11201704829QA (en)	2017-07-28	Methods and compositions for treating brain diseases
IL253847A0 (en)	2017-09-28	Methods of treating diseases
PL3137097T3 (en)	2023-09-11	Treatment and prevention of alzheimer's disease (ad)
IL254252A0 (en)	2017-10-31	Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease
PL3137094T3 (en)	2023-03-13	Treatment and prevention of alzheimer's disease (ad)
IL251135A0 (en)	2017-04-30	Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases
EP3244897A4 (en)	2018-08-22	Methods for treating alzheimer's disease
HUE037501T2 (en)	2018-08-28	Treatment and prevention of alzheimer's disease (ad)
GB201622116D0 (en)	2017-02-08	Treatment of liver disease
GB201511453D0 (en)	2015-08-12	Treatment of alzheimer's disease
GB201621398D0 (en)	2017-02-01	Treatment of emt-associated disease
GB201414038D0 (en)	2014-09-24	Alzheimer's disease
GB201504144D0 (en)	2015-04-22	Treatment of Parkinson's disease
GB201504413D0 (en)	2015-04-29	Treatment of disease
GB201518052D0 (en)	2015-11-25	Parkinson's disease treatment